KR20170021745A - 티모신 β4 및 시트르산을 유효성분으로 포함하는 각막 손상 예방 또는 치료용 조성물 - Google Patents

티모신 β4 및 시트르산을 유효성분으로 포함하는 각막 손상 예방 또는 치료용 조성물

Info

Publication number
KR20170021745A
KR20170021745A KR1020160103066A KR20160103066A KR20170021745A KR 20170021745 A KR20170021745 A KR 20170021745A KR 1020160103066 A KR1020160103066 A KR 1020160103066A KR 20160103066 A KR20160103066 A KR 20160103066A KR 20170021745 A KR20170021745 A KR 20170021745A
Authority
KR
South Korea
Prior art keywords
composition
salt
citric acid
acid
thymosin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020160103066A
Other languages
English (en)
Korean (ko)
Inventor
강신욱
김경순
성지혜
Original Assignee
주식회사 지트리비앤티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 지트리비앤티 filed Critical 주식회사 지트리비앤티
Publication of KR20170021745A publication Critical patent/KR20170021745A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020160103066A 2015-08-18 2016-08-12 티모신 β4 및 시트르산을 유효성분으로 포함하는 각막 손상 예방 또는 치료용 조성물 Withdrawn KR20170021745A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150116089 2015-08-18
KR1020150116089 2015-08-18

Publications (1)

Publication Number Publication Date
KR20170021745A true KR20170021745A (ko) 2017-02-28

Family

ID=58050857

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020160103066A Withdrawn KR20170021745A (ko) 2015-08-18 2016-08-12 티모신 β4 및 시트르산을 유효성분으로 포함하는 각막 손상 예방 또는 치료용 조성물

Country Status (6)

Country Link
US (1) US9867868B2 (enExample)
EP (1) EP3338792B1 (enExample)
JP (1) JP6910072B2 (enExample)
KR (1) KR20170021745A (enExample)
ES (1) ES2895923T3 (enExample)
WO (1) WO2017030328A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3372159A1 (en) 2017-02-17 2018-09-12 Samsung Electronics Co., Ltd. Electronic device and body composition analyzing method
WO2018230858A3 (ko) * 2017-06-14 2019-02-07 (주)휴온스 Gly-Tβ4 (Gly-티모신β4)을 함유하는 안구건조증 치료용 약학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080033939A (ko) 2005-06-17 2008-04-17 리지너크스 바이오 파마소티컬스, 인코포레이티드 동결 건조된 형태이거나, 또는 동결 건조될 수 있는 형태인엘케이케이티이티 및/또는 엘케이케이티엔티 펩티드조성물들

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264360A1 (en) * 2002-04-12 2006-11-23 Yale University Office Of Cooperstive Research Anti-inflammatory and wound healing effects of lymphoid thymosin beta-4
WO2008108927A2 (en) * 2007-03-06 2008-09-12 Regenerx Biopharmaceuticals, Inc. Methods and compositions for stabilizing polypeptides
WO2009007839A1 (en) * 2007-07-11 2009-01-15 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
CN104758921A (zh) * 2010-11-08 2015-07-08 希尔洛有限公司 缓冲的眼用组合物以及使用其的方法
EP3210614A4 (en) * 2014-10-22 2018-06-13 G-Treebnt Co., Ltd. Composition containing thymosin beta 4, and pharmaceutical formulation comprising same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080033939A (ko) 2005-06-17 2008-04-17 리지너크스 바이오 파마소티컬스, 인코포레이티드 동결 건조된 형태이거나, 또는 동결 건조될 수 있는 형태인엘케이케이티이티 및/또는 엘케이케이티엔티 펩티드조성물들

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3372159A1 (en) 2017-02-17 2018-09-12 Samsung Electronics Co., Ltd. Electronic device and body composition analyzing method
WO2018230858A3 (ko) * 2017-06-14 2019-02-07 (주)휴온스 Gly-Tβ4 (Gly-티모신β4)을 함유하는 안구건조증 치료용 약학적 조성물

Also Published As

Publication number Publication date
US20170049857A1 (en) 2017-02-23
US9867868B2 (en) 2018-01-16
EP3338792B1 (en) 2021-09-29
EP3338792A1 (en) 2018-06-27
JP2018523648A (ja) 2018-08-23
JP6910072B2 (ja) 2021-07-28
ES2895923T3 (es) 2022-02-23
WO2017030328A1 (ko) 2017-02-23
EP3338792A4 (en) 2019-05-15

Similar Documents

Publication Publication Date Title
US11759499B2 (en) Compositions and methods for prevention and treatment of corneal haze and scarring
IL218504A (en) Use of lkktet and / or lkktnt peptides to treat dry eye syndrome
AU2006260184B2 (en) Prophylactic or therapeutic agent for corneal/conjunctival disease
EP3338792B1 (en) Corneal damage prevention/treatment composition comprising thymosin beta 4 and citric acid as active ingredients
KR101910908B1 (ko) Gly-Tβ4 (Gly-티모신β4)을 함유하는 안구건조증 치료용 약학적 조성물
EP3484497A1 (en) Methods of treating dry eye syndrome
KR102790252B1 (ko) 각막 손상 또는 안구건조증 예방 또는 치료용 조성물
KR20170021667A (ko) 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물
HK40012612A (en) Methods of treating dry eye syndrome
JPWO1999043347A1 (ja) 角膜上皮障害症治療剤
KR20160091836A (ko) 뉴레귤린을 포함하는 상처 또는 안구건조증의 치료용 약학 조성물
US20140213605A1 (en) Methods for treating eye disorders using opioid receptor antagonists

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20160812

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid